

Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

CD20 antibody [EP459Y] - Carboxyterminal end

RRID:AB_1640323

Type: Antibody

Proper Citation

Abcam Cat# ab78237, RRID:AB_1640323

Antibody Information

URL: http://antibodyregistry.org/AB_1640323

Proper Citation: Abcam Cat# ab78237, RRID:AB_1640323

Target Antigen: CD20 antibody [EP459Y] - Carboxyterminal end

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Flow Cytometry; Western Blot; Immunohistochemistry - fixed; Immunohistochemistry; Immunoprecipitation; Flow Cyt, IHC-P, IP, WB

Antibody Name: CD20 antibody [EP459Y] - Carboxyterminal end

Description: This monoclonal targets CD20 antibody [EP459Y] - Carboxyterminal end

Target Organism: monkey, human

Antibody ID: AB_1640323

Vendor: Abcam

Catalog Number: ab78237

Record Creation Time: 20250820T032213+0000

Record Last Update: 20250820T160417+0000

Ratings and Alerts

No rating or validation information has been found for CD20 antibody [EP459Y] - Carboxyterminal end.

No alerts have been found for CD20 antibody [EP459Y] - Carboxyterminal end.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

He G, et al. (2026) Vesicle trafficking 1 in breast cancer tissue and serum orchestrates metastatic progression and an immunosuppressive microenvironment. International immunopharmacology, 178, 116564.

Xu Y, et al. (2026) Ultra-precision deconvolution of spatial transcriptomics decodes immune heterogeneity and fate-defining programs in tissues. Nature communications, 17(1).

Chen S, et al. (2026) PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma. Cancer cell.

Xia TL, et al. (2025) TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial. Med (New York, N.Y.), 6(11), 100846.

Zhang YP, et al. (2025) PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. Cancer cell, 43(5), 856.

Xing X, et al. (2025) Pan-cancer human brain metastases atlas at single-cell resolution. Cancer cell, 43(7), 1242.

Quandt Z, et al. (2025) Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. Journal for immunotherapy of cancer, 13(8).

Xing R, et al. (2025) Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. Cell reports. Medicine, 6(9), 102298.

Li X, et al. (2025) Integrated spatial transcriptomic profiling to dissect the cellular characteristics of tumor-associated tertiary lymphoid structures. Cell reports, 44(9), 116250.

Tang Z, et al. (2025) Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. Cancer cell, 43(6), 1025.

Peng T, et al. (2025) Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy. *Cell stem cell*, 32(4), 652.

Zhang Y, et al. (2025) Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. *Cancer cell*, 43(3), 446.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Stupichev D, et al. (2025) AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma. *Cell reports. Medicine*, 6(8), 102299.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. *Cancer cell*, 42(1), 135.

Chen S, et al. (2024) Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance. *NPJ precision oncology*, 8(1), 159.

Chen Y, et al. (2024) Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. *Cancer cell*, 42(7), 1268.

Liu Z, et al. (2023) Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. *Cancer cell*, 41(11), 1852.

Hong J, et al. (2023) Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection. *Cell reports. Medicine*, 4(11), 101296.

Liu Z, et al. (2023) Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. *Cancer cell*, 41(1), 181.